Scemblix 20 mg and 40 mg film-coated tablets
*Company:
Novartis Ireland LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may not be renewed (A)Active Ingredient(s):
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company
Updated on 19 April 2024
File name
Scemblix_REG SPC_PF24-0082_Feb 2024_clean.pdf
Reasons for updating
- Change to section 5.3 - Preclinical safety data
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 25 January 2024
File name
Scemblix_REG SPC_PF24-0018_Jan 2024_clean.pdf
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.2 - Pharmacokinetic properties
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 25 January 2024
File name
Scemblix_R89_REG PIL_PF24-0018_Clean_14.12.2023.pdf
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
Updated on 01 November 2023
File name
Scemblix_REG SPC_PF23-0131_July 2023_clean.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 01 November 2023
File name
Scemblix_REG PIL_Clean_24.07.2023_.pdf
Reasons for updating
- New PIL for new product